文献速递冠心病心力衰竭与心肌病

STICH试验:缺血性心力衰竭患者接受外科血运重建的性别差异

Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).
PubMed 文献 · Circulation · 2018-01-01

STICH试验随机纳入1212例冠心病伴左室射血分数≤35%患者(女性148例,12%),比较CABG+药物治疗与单纯药物治疗的10年结局。女性全因死亡和心血管死亡显著低于男性,但性别与治疗组间无显著交互作用,CABG获益不受性别影响。

要点

  • 女性全因死亡(49.0% vs 65.8%)和心血管死亡(34.3% vs 52.3%)均低于男性。
  • 性别与CABG+药物 vs 药物的交互作用在全因死亡、心血管死亡及复合终点均无统计学意义。
  • 性别不应影响缺血性左室功能不全患者关于CABG的治疗决策。

核心结论

  • 性别与CABG+药物治疗相比单纯药物治疗在全因死亡、心血管死亡、死亡或心血管住院复合终点及手术死亡方面的效应无关。
  • 因此,性别不应影响这些患者关于CABG的治疗决策。

研究设计与样本

  • STICH试验随机对照研究,纳入1212例冠心病伴左室射血分数≤35%患者,其中女性148例(12%),男性1064例(88%)。
  • 患者随机接受CABG+药物治疗(MED)或单纯MED,按性别比较10年长期结局。

主要发现

  • 基线时女性较男性年龄更大(63.4 vs 59.3岁;P=0.016),体重指数更高(27.9 vs 26.7 kg/m2;P=0.001)。
  • 女性糖尿病(55.4% vs 37.2%)、高血压(70.9% vs 58.6%)、高脂血症(70.3% vs 58.9%)比例更高,吸烟比例更低(13.5% vs 21.8%),既往CABG更低(0% vs 3.4%),均P<0.05。
  • 女性NYHA III/IV级比例更高(66.2% vs 57.0%),6分钟步行距离更短(300 vs 350 m),KCCQ总分更低(51 vs 63),均P<0.05。
  • 10年随访中,女性全因死亡(49.0% vs 65.8%;调整HR 0.67;95%CI 0.52-0.86;P=0.002)和心血管死亡(34.3% vs 52.3%;调整HR 0.65;95%CI 0.48-0.89;P=0.006)显著低于男性。
  • 随机接受CABG+MED vs MED,性别与治疗组在全因死亡、心血管死亡或全因死亡/心血管住院复合终点均无显著交互作用(均P>0.05)。

临床怎么用

  • 对于缺血性左室功能不全患者,性别不应作为选择CABG或药物治疗的依据。
  • 女性患者接受CABG+药物治疗的长期获益与男性无显著差异,治疗决策应基于整体临床情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female sex is conventionally considered a risk factor for coronary artery bypass grafting (CABG) and has been included as a poor prognostic factor in multiple cardiac operative risk evaluation scores. We aimed to investigate the association of sex and the long-term benefit of CABG in patients with ischemic left ventricular dysfunction enrolled in the prospective STICH trial (Surgical Treatment for Ischemic Heart Failure Study). METHODS: The STICH trial randomized 1212 patients (148 [12%] women and 1064 [88%] men) with coronary artery disease and left ventricular ejection fraction ≤35% to CABG+medical therapy (MED) versus MED alone. Long-term (10-year) outcomes with each treatment were compared according to sex. RESULTS: At baseline, women were older (63.4 versus 59.3 years; P=0.016) with higher body mass index (27.9 versus 26.7 kg/m2; P=0.001). Women had more coronary artery disease risk factors (diabetes mellitus, 55.4% versus 37.2%; hypertension, 70.9% versus 58.6%; hyperlipidemia, 70.3% versus 58.9%) except for smoking (13.5% versus 21.8%) and had lower rates of prior CABG (0% versus 3.4%; all P<0.05) than men. Moreover, women had higher New York Heart Association class (class III/IV, 66.2% versus 57.0%), lower 6-minute walk capacity (300 versus 350 m), and lower Kansas City Cardiomyopathy Questionnaire overall summary scores (51 versus 63; all P<0.05). Over 10 years of follow-up, all-cause mortality (49.0% versus 65.8%; adjusted hazard ratio, 0.67; 95% confidence interval, 0.52-0.86; P=0.002) and cardiovascular mortality (34.3% versus 52.3%; adjusted hazard ratio, 0.65; 95% confidence interval, 0.48-0.89; P=0.006) were significantly lower in women compared with men. With randomization to CABG+MED versus MED treatment, there was no significant interaction between sex and treatment group in all-cause mortality, cardiovascular mortality, or the composite of all-cause mortality or cardiovascular hospitalization (all P>0.05). In addition, surgical deaths were not statistically different (1.5% versus 5.1%; P=0.187) between sexes among patients randomized to CABG per protocol as initial treatment. CONCLUSIONS: Sex is not associated with the effect of CABG+MED versus MED on all-cause mortality, cardiovascular mortality, the composite of death or cardiovascular hospitalization, or surgical deaths in patients with ischemic left ventricular dysfunction. Thus, sex should not influence treatment decisions about CABG in these patients. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00023595.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Piña IL, Zheng Q, She L, et al. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2018. PMID: 29459462. doi:10.1161/CIRCULATIONAHA.117.030526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。